Literature DB >> 24614404

Immunology: TREG cells in transplantation-a double-edged sword?

Fadi G Lakkis1.   

Abstract

Immunosuppressive drugs commonly used in transplantation and autoimmune diseases are unfortunately associated with increased cancer incidence. Now, a new study reports a direct relationship between the number of regulatory T cells in the blood and the risk of developing invasive skin cancer in kidney transplant recipients.

Entities:  

Mesh：

Year:  2014        PMID： 24614404     DOI： 10.1038/nrneph.2014.35

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


  10 in total

1.  The number of human peripheral blood CD4+ CD25high regulatory T cells increases with age.

Authors:  R Gregg; C M Smith; F J Clark; D Dunnion; N Khan; R Chakraverty; L Nayak; P A Moss
Journal:  Clin Exp Immunol       Date:  2005-06       Impact factor: 4.330

Review 2.  Regulatory T-cell therapy in transplantation: moving to the clinic.

Authors:  Qizhi Tang; Jeffrey A Bluestone
Journal:  Cold Spring Harb Perspect Med       Date:  2013-11-01       Impact factor: 6.915

3.  Non-melanoma skin cancer risk in the Queensland renal transplant population.

Authors:  H M Ramsay; A A Fryer; C M Hawley; A G Smith; P N Harden
Journal:  Br J Dermatol       Date:  2002-11       Impact factor: 9.302

Review 4.  Update on the long-term complications of renal transplantation.

Authors:  Matthew J Bottomley; Paul N Harden
Journal:  Br Med Bull       Date:  2013-05-02       Impact factor: 4.291

Review 5.  Regulatory T cells in cancer immunotherapy.

Authors:  Hiroyoshi Nishikawa; Shimon Sakaguchi
Journal:  Curr Opin Immunol       Date:  2014-01-14       Impact factor: 7.486

Review 6.  FOXP3+ regulatory T cells in the human immune system.

Authors:  Shimon Sakaguchi; Makoto Miyara; Cristina M Costantino; David A Hafler
Journal:  Nat Rev Immunol       Date:  2010-06-18       Impact factor: 53.106

Review 7.  Regulatory T cells and the immune aging process: a mini-review.

Authors:  Ann Jagger; Yasuhiro Shimojima; Jorg J Goronzy; Cornelia M Weyand
Journal:  Gerontology       Date:  2013-11-28       Impact factor: 5.140

8.  The immune phenotype may relate to cancer development in kidney transplant recipients.

Authors:  Christopher M Hope; Blair S Grace; Katherine R Pilkington; Patrick T Coates; Ivo P Bergmann; Robert P Carroll
Journal:  Kidney Int       Date:  2014-01-15       Impact factor: 10.612

9.  Functional regulatory T cells accumulate in aged hosts and promote chronic infectious disease reactivation.

Authors:  Celine S Lages; Isabelle Suffia; Paula A Velilla; Bin Huang; Gregg Warshaw; David A Hildeman; Yasmin Belkaid; Claire Chougnet
Journal:  J Immunol       Date:  2008-08-01       Impact factor: 5.422

10.  Immunologic human renal allograft injury associates with an altered IL-10/TNF-α expression ratio in regulatory B cells.

Authors:  Aravind Cherukuri; David M Rothstein; Brendan Clark; Clive R Carter; Adam Davison; Maria Hernandez-Fuentes; Eric Hewitt; Alan D Salama; Richard J Baker
Journal:  J Am Soc Nephrol       Date:  2014-03-07       Impact factor: 10.121
  10 in total
  3 in total

1.  As a prognostic biomarker of clear cell renal cell carcinoma RUFY4 predicts immunotherapy responsiveness in a PDL1-related manner.

Authors:  Daojia Miao; Jian Shi; Zhiyong Xiong; Wen Xiao; Xiangui Meng; Qingyang Lv; Kairu Xie; Hongmei Yang; Xiaoping Zhang
Journal:  Cancer Cell Int       Date:  2022-02-08       Impact factor: 5.722

2.  Identifying hub genes of clear cell renal cell carcinoma associated with the proportion of regulatory T cells by weighted gene co-expression network analysis.

Authors:  Ye-Hui Chen; Shao-Hao Chen; Jian Hou; Zhi-Bin Ke; Yu-Peng Wu; Ting-Ting Lin; Yong Wei; Xue-Yi Xue; Qing-Shui Zheng; Jin-Bei Huang; Ning Xu
Journal:  Aging (Albany NY)       Date:  2019-10-31       Impact factor: 5.682

3.  Netrin-1 reduces lung ischemia-reperfusion injury by increasing the proportion of regulatory T cells.

Authors:  Zhili Chen; Yuxi Chen; Jue Zhou; Yong Li; Changyao Gong; Xiaobo Wang
Journal:  J Int Med Res       Date:  2020-06       Impact factor: 1.671
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.